[1] Supply Chain Monitoring & Risk Identification ------------------------------------------------- | Real-time data from: | | • USP Medicine Supply Map | | • FDA Shortage List | | • Angels for Change Drug Crisis Hotline | | • Clinical & patient advocacy insights | ------------------------------------------------- | ▼ [2] Drug Selection & Risk Assessment ------------------------------------------------- | Stakeholders assess: | | • Clinical priority | | • Supply chain vulnerability | | • Shortage frequency and duration | | • Lack of therapeutic alternatives | ------------------------------------------------- | ▼ [3] Buffer Inventory Deployment (Proactive Phase) ------------------------------------------------- | Partner manufacturers (e.g., Fresenius Kabi) | | produce and rotate inventory | | Strategic storage via Cencora / McKesson | | Onshore U.S. warehousing for rapid release | ------------------------------------------------- | ▼ [4] Early Warning & Real-Time Activation ------------------------------------------------- | Hotline / GSSN receives shortage alert | | or early signal via monitoring tools | | A4C verifies clinical need and coordinates | | rapid release | ------------------------------------------------- | ▼ [5] Emergency Allocation & Delivery ------------------------------------------------- | Medications deployed to: | | • Hospitals | | • Cancer centers | | • Pharmacies | | • Direct to physicians (as needed) | | Ensures continuity of care | ------------------------------------------------- | ▼ [6] Feedback, Replenishment & Scalability ------------------------------------------------- | Partners provide usage data and outcomes | | Supply is rotated and replenished proactively | | Model scaled to include additional drugs | | New collaborators invited to join | -------------------------------------------------